Drugs & Targets FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML May 15, 2026Vol.52 No.19
Drugs & Targets Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program May 15, 2026Vol.52 No.19
Drugs & Targets FDA clears AI digital pathology risk stratification tool in breast cancer May 15, 2026Vol.52 No.19
Podcast Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now) May 13, 2026
Regulatory News Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC May 08, 2026Vol.52 No.18By Jacquelyn Cobb
Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel May 08, 2026Vol.52 No.18By Paul Goldberg
Cancer Policy Katherine Szarama steps in as CBER acting director, replacing Prasad May 08, 2026Vol.52 No.18By Claire Marie Porter
Funding Opportunities FDA’s OCE announces funding opportunity in ultra-rare cancers May 08, 2026Vol.52 No.18
Drugs & Targets FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib May 08, 2026Vol.52 No.18By Claire Marie Porter
